Ly-GDI/RhoGDI2/ARHGDIB Antibody (D-7): sc-271108

Ly-GDI Antibody (D-7) is a mouse monoclonal IgG1 antibody that detects Ly-GDI in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). Ly-GDI, a member of the Rho guanine nucleotide dissociation inhibitor (GDI) subfamily, plays a crucial role in regulating the activity of Rho GTPases, which are essential for numerous cellular processes such as cytoskeletal dynamics, cell migration, and proliferation. Ly-GDI′s primary function is to maintain Rho GTPases in their inactive GDP-bound state, thereby preventing unintended activation of signaling pathways that could lead to aberrant cell behavior. This regulatory mechanism is vital for maintaining cellular homeostasis and ensuring proper responses to extracellular signals. Notably, Ly-GDI is predominantly expressed in hematopoietic cells, particularly in B and T lymphocyte cell lines, highlighting its importance in immune system function. Ly-GDI′s ability to interact with various Ras-like GTP-binding proteins, including Rho A, Rho B, Rac, and Cdc42, underscores its significance in modulating the signaling networks that govern cell fate and behavior. With robust performance in multiple applications, anti-Ly-GDI antibody (D-7) is an invaluable tool for researchers investigating the intricate roles of Rho GTPases in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Ly-GDI/RhoGDI2/ARHGDIB Antibody (D-7) References:

1. Nuclear translocation of cleaved LyGDI dissociated from Rho and Rac during Trp53-dependent ionizing radiation-induced apoptosis of thymus cells in vitro.  |  Zhou, X., et al. 2004. Radiat Res. 162: 287-95. PMID: 15332996
2. RhoGDIbeta lacking the N-terminal regulatory domain suppresses metastasis by promoting anoikis in v-src-transformed cells.  |  Ota, T., et al. 2006. Clin Exp Metastasis. 23: 323-34. PMID: 17111235
3. ZAK negatively regulates RhoGDIbeta-induced Rac1-mediated hypertrophic growth and cell migration.  |  Huang, CY., et al. 2009. J Biomed Sci. 16: 56. PMID: 19538723
4. Centrosomal localization of RhoGDIβ and its relevance to mitotic processes in cancer cells.  |  Jiang, YS., et al. 2013. Int J Oncol. 42: 460-8. PMID: 23232495
5. RhoGDIβ Inhibits Bone Morphogenetic Protein 4 (BMP4)-induced Adipocyte Lineage Commitment and Favors Smooth Muscle-like Cell Differentiation.  |  Huang, HY., et al. 2015. J Biol Chem. 290: 11119-29. PMID: 25778399
6. Radiation-Induced RhoGDIβ Cleavage Leads to Perturbation of Cell Polarity: A Possible Link to Cancer Spreading.  |  Fujiwara, M., et al. 2016. J Cell Physiol. 231: 2493-505. PMID: 26919575
7. RhoGDIβ promotes Sp1/MMP-2 expression and bladder cancer invasion through perturbing miR-200c-targeted JNK2 protein translation.  |  Huang, H., et al. 2017. Mol Oncol. 11: 1579-1594. PMID: 28846829
8. NFκB2 p52 stabilizes rhogdiβ mRNA by inhibiting AUF1 protein degradation via a miR-145/Sp1/USP8-dependent axis.  |  Xu, J., et al. 2019. Mol Carcinog. 58: 777-793. PMID: 30604907
9. Paradoxical regulation of glucose-induced Rac1 activation and insulin secretion by RhoGDIβ in pancreatic β-cells.  |  Thamilselvan, V. and Kowluru, A. 2021. Small GTPases. 12: 114-121. PMID: 31267831
10. Hyperglycemic Stress Induces Expression, Degradation, and Nuclear Association of Rho GDP Dissociation Inhibitor 2 (RhoGDIβ) in Pancreatic β-Cells.  |  Gleason, N. and Kowluru, A. 2024. Cells. 13: PMID: 38334664

The preferred Ly-GDI/RhoGDI2/ARHGDIB antibody is Ly-GDI/RhoGDI2/ARHGDIB Antibody (G-12): sc-376473.